Cluster protocols in SCIT: Enough evidence for practical use?

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 3, 2010, Pages 188-193

  Pfaar, Oliver ^a   Leitzbach, Sarah ^a   Hörmann, Karl ^a   Klimek, Ludger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergic rhinoconjunctivitis; Cluster immunotherapy; Cluster protocols; Specific hyposensitization; Specific subcutaneous immunotherapy

Indexed keywords

ALLERGEN; HOUSE DUST ALLERGEN; IMMUNOLOGIC AGENT; PLACEBO; POLLEN ANTIGEN;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANAPHYLAXIS; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOTHERAPY; INJECTION SITE REACTION; MAINTENANCE DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; PATIENT SCHEDULING; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS; SENSITIZATION; SHOCK; SYSTEMIC DISEASE; TREATMENT DURATION;

ALLERGENS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 77951877208     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328339505c     Document Type: Review

References (36)

1. Bousquet J, Lockey RF, Malling HJ. WHO position paper: allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:1-42.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on •• Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160. Latest GALEN update on allergic rhinitis and SIT.
3. Compalati E, Penagos M, Tarantini F, et al. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102:22-28.
4. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; CD001936.
5. Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol 2006;97:126-137.
6. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-974.
7. Cox LS. Shooting for a faster approach to the immunotherapy target: will cluster become conventional? Ann Allergy Asthma Immunol 2009;102:177-178.
8. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immunotherapy. J Allergy Clin Immunol 1993;91:734-737.
9. Cox L. Allergen immunotherapy and asthma: efficacy, safety, and other considerations. Allergy Asthma Proc 2008;29:580-589.
10. Pfaar O, Hormann K, Klimek L. Cluster-immunotherapy in allergic rhinoconjunctivitis: a review of an innovative, new therapeutic approach. Allergologie 2009;32:433-440.
11. Freeman J. Rush inoculation with special reference to hay fever treatment. Lancet 1930;744-747.
12. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006;61(Suppl 82):1-20.
13. Malling H, Weeke B. Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993;48:7-35.
14. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same •• language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010;125:569-574. A recently published, five-stage grading system for systemic reactions related to SCIT by the World Allergy Organisation (WAO), which will be commonly used in future clinical trials and surveillance studies.
15. Weber R, Vaughan T, Dolen WK. A 10-year review of adverse actions to immunotherapy. JACI 1988;81:295.
16. Walker SM, Varney VA, Gaga M, et al. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405-413.
17. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90:567-578.
18. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323-332.
19. Lüderitz-Püchel U, Keller-Stanislawski B, Haustein D. Risk reevaluation of diagnostic and therapeutic allergen extracts: an analysis of adverse drug reactions from 1991 to 2000. Bundesgesundheitsbl-Gesundheitsforsch- Gesundheitsschutz 2001;44:709-718.
20. Kleine-Tebbe J, Bufe A, Ebner C, et al. Specific immunotherapy (hyposensitization) for IgE-mediated allergic diseases. Allergo J 2009;18:508-537.
21. Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 1981;68:460-470.
22. Tabar AI, Muro MD, Garcia BE, et al. Dermatophagoides pteronyssinus cluster immunotherapy: a controlled trial of safety and clinical efficacy. J Investig Allergol Clin Immunol 1999;9:155-164.
23. Hansen I, Stuck BA, Schneider-Gene S, et al. Specific immunotherapy in allergic rhinoconjunctivitis: Current standard and new approaches. Allergologie 2002;25:549-556.
24. Moreno C, Fernandez-Tavora L, Acero S, et al. Tolerance of a cluster schedule on the treatment of seasonal allergic respiratory disease with pollen extracts quantified in mass units. J Investig Allergol Clin Immunol 2003;13:221-227.
25. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005;116:109-118.
26. Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster • specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol 2009;148:251-260. Recently published study on asthmatic children and immunological effects of cluster SCIT in comparison to conventional protocols.
27. Pfaar O, Klimek L, Fischer I, et al. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol 2009;150:102-108.
28. Subiza J, Feliu A, Subiza JL, et al. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2. 5 months of treatment. Clin Exp Allergy 2008;38:987-994.
29. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy: relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000;30:1423-1429.
30. Serrano P, Algorta J, Martinez A, et al. Prospective safety study of immunotherapy administered in a cluster schedule. J Investig Allergol Clin Immunol 2004;14:312-319.
31. Casanovas M, Martin R, Jimenez C, et al. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol 2006;139:153-158.
32. Serrano P, Justicia JL, Sanchez C, et al. Systemic tolerability of specific • subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol 2009;102:247-252. Multicenter retrospective study on 1147 adult allergic patients comparing the safety profile of different cluster protocols.
33. Pfaar O, Mosges R, Hormann K, Klimek L. Safety aspects of cluster-immu-• notherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol 2010;267:245-250. Recently published prospective, open-label study on almost 400 pollen allergic patients.
34. Zhang L, Wang C, Han D, et al. Comparative study of cluster and conventional •• immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol 2009;148:161-169. Prospective study with 'head-to-head' comparison of cluster and conventional SCIT protocols: safety profile, clinical and immunological effects.
35. Pfaar O, Mösges R, Hörmann K, Klimek L. Cluster immunotherapy of persistent allergic rhinoconjunctivitis: safety aspects of induction therapy with mite depot allergen preparations. HNO 2009;57:1099-1105.
36. Mauro M, Russello M, Alesina R, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol 2006;38:31-34.